Zogenix, Inc. reported positive top-line results from its second confirmatory Phase 3 study (Study 1504) for its investigational drug, ZX008 (low-dose fenfluramine hydrochloride), for the treatment of children and young adults with Dravet syndrome. The study results, which are consistent with those reported in Study 1, Zogenix’s first pivotal Phase 3 study, successfully met the primary endpoint and all key secondary endpoints, demonstrating that ZX008, at a dose of 0.5 mg/kg/day (maximum 20 mg/day), is superior to placebo when added to a stiripentol regimen.
July 12, 2018
January 27, 2023
Frequency of and Factors Associated with Antiseizure Medication Discontinuation Discussions and Decisions in Patients with Epilepsy: a Multicenter Retrospective Chart Review
Only approximately half of patients with prolonged seizure-freedom had a documented discussion about antiseizure medication discontinuation. Discontinuation was fairly rare even among low-risk patients.